One has FDA approval and one is a long way off finishing a P2.
The width of the market cap gap is in proportion to Mesoblast being 'more advanced'? If MSB was managed better the gap would be far greater - so then CYP would be even better investment? How does it even make sense? Because they ultimately believe CYP holds the superior technology? Bloody Nora. This article is suggesting CYP will outstrip MSB and maintain it's current market cap. This article is utter rubbish on every level.
No mention of not needing to do a P3. 'Maybe, just maybe...' as KK has said multiple times.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)